Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Stopped The study has been terminated early by the sponsor due to business decision.
Conditions
- Merkel Cell Carcinoma
- Small Cell Lung Cancer
Interventions
- BIOLOGICAL: XmAb18087
- DRUG: XmAb18087 ± Pembrolizumab
Sponsor
Xencor, Inc.
Collaborators